sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate | 942594-93-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate
• 英文别名: Ren-001；sodium;2-[4-[(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-ylprop-1-ynyl)phenyl]prop-2-enoxy]-2-methylphenoxy]acetate
• CAS: 942594-93-6；1604815-32-8
• 化学式: C₃₁H₂₉FNO₅*Na
• 分子量: 537.563
• InChiKey: FDJYWCAHISUZAI-MAOGHAJMSA-M

物化性质

• 沸点：
  708.3±60.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  0.46
• 重原子数：
  39
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  71.1
• 氢给体数：
  0
• 氢受体数：
  7

制备方法与用途

生物活性

PPARδ agonist是 PPARδ 的激动剂，来自专利US20180071304， 化合物实例10。

靶点

PPARδ

反应信息

• 作为产物：
  描述：

  4-羟基-3-甲基苯乙酮 在 甲醇 、 水 、 potassium carbonate 、 caesium carbonate 、 间氯过氧苯甲酸 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 反应 124.0h， 生成 sodium (E)-2-(4-((3-(4-fluorophenyl)-3-(4-(3-morpholinoprop-1-yn-1-yl)phenyl)allyl)oxy)-2-methylphenoxy)acetate
  参考文献：
  名称：

  [EN] METHODS OF MAKING A PPAR-DELTA AGONIST
  [FR] PROCÉDÉS DE PRÉPARATION D'UN AGONISTE DE PPAR-DELTA

  摘要：

  本文描述了制备PPARδ激动剂(E)-2-(4-((3-(4-氟苯基)-3-(4-(3-吗啡啶基丙炔-1-基)苯基)烯丙氧基)-2-甲基苯氧)乙酸及其盐形式的方法。

  公开号：

  WO2022115326A1

文献信息

• Use of a PPAR-δ agonist for reducing loss of muscle strength, muscle mass, or type I muscle fibers in an immobilized limb
  申请人：vTv Therapeutics LLC

  公开号：US10456406B2

  公开（公告）日：2019-10-29

  The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.

  本发明提供了通过施用(E)-[4-[3-(4-氟苯基)-3-[4-[3-(吗啉-4-基)丙炔基]苯基]烯丙氧基]-2-甲基-苯氧基]乙酸或其药学上可接受的盐来减少固定肢体的肌力、肌肉质量或 I 型肌纤维损失的方法。
• USE OF A PPAR-DELTA AGONIST FOR REDUCING LOSS OF MUSCLE STRENGTH, MUSCLE MASS, OR TYPE I MUSCLE FIBERS IN AN IMMOBILIZED LIMB
  申请人：vTv Therapeutics LLC

  公开号：US20170027950A1

  公开（公告）日：2017-02-02

  The present invention provides methods for reducing loss of muscle strength, muscle mass, or Type I muscle fibers in an immobilized limb by administering (E)-[4-[3-(4-Fluorophenyl)-3-[4-[3-(morpholin-4-yl)propynyl]phenyl]allyloxy]-2-methyl-phenoxy]acetic acid or a pharmaceutically acceptable salt thereof.
• USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD)
  申请人：Reneo Pharmaceuticals, Inc.

  公开号：US20220023306A1

  公开（公告）日：2022-01-27

  Described herein is the use of PPARδ agonists in the treatment of fatty acid oxidation disorders.
• USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY
  申请人：Reneo Pharmaceuticals, Inc.

  公开号：US20220117972A1

  公开（公告）日：2022-04-21

  Described herein is the use of PPARδ agonists in the treatment of mitochondrial myopathy. In one aspect, described herein are methods for treating a primary mitochondrial myopathy (PMM) in a mammal comprising administering to the mammal with a primary mitochondrial myopathy a peroxisome proliferator-activated receptor delta (PPARδ) agonist compound. In another aspect, described herein is a method of modulating PPARδ in a mammal with primary mitochondrial myopathy comprising administering to the mammal with primary mitochondrial myopathy PPARδ agonist compound.
• USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE
  申请人：Reneo Pharmaceuticals, Inc.

  公开号：US20220370467A1

  公开（公告）日：2022-11-24

  Described herein is the use of a PPAR-delta agonist in the treatment of kidney diseases, wherein: the kidney disease is Alport syndrome, Goodpasture syndrome, thin basement membrane nephropathy (TBMN), focal segmental glomerulosclerosis (FSGS), benign familial hematuria (BFH), post-transplant anti-GBM (Glomerular Basement Membrane) nephritis, X-linked Alport syndrome (XLAS), autosomal recessive Alport syndrome (ARAS) or autosomal dominant Alport syndrome (ADAS).